Johnson & Johnson

Johnson & Johnson shares trade near the midpoint of their 52-week range, with a P/E of 29.9x and a net margin of 21.5%. Revenue rose 8.1% year-over-year, but EPS fell 7.8%, reflecting cost pressures or share-count effects that investors will watch on the next call. The Alpha Score of 61.9 is driven by momentum (83.3), while value (48.2) and sentiment (50) sit neutral. Quality scores 59.3. The divergence between top-line growth and bottom-line contraction is the metric to track this quarter.

Johnson & Johnson shares have drifted from their 52-week high, with the stock now trading near $190. The company's 8.1% revenue growth masks a 7.8% earnings-per-share decline, a divergence that has weighed on sentiment. Net margins remain healthy at 21.5%, but the P/E of 29.93 leaves little room for error if earnings continue to contract. The Alpha Score of 61.5 is pulled upward by momentum at 81.9, while value scores a weak 48.2 and sentiment sits at 50. That split suggests the stock is riding recent price strength rather than fundamental re-rating. Watch for the next quarterly report to see whether the EPS decline narrows or accelerates.

Johnson & Johnson carries an Alpha Score of 61.7, with momentum at 82.7 pulling the bulk of the weight. Revenue grew 8.1% year over year, pushing the company toward $100 billion in sales. Net margin sits at 21.5%, a healthy number for a healthcare giant. The P/E of 29.93 is elevated relative to the broader market, but the dividend streak — 64 years and counting — tops Abbott's 54-year run. Earnings per share fell 7.8% from a year ago, a point that bears will note. The stock trades near the top of its 52-week range, having gained 60% from the low. The ETF comparison between FHLC and PJP highlights sector allocations, but for JNJ specifically, the dividend record and revenue trajectory are the main supports. Next quarter's sales figure will determine whether the $100 billion threshold is breached.

Johnson & Johnson sits near the top of its 52-week range at $274.90, with a momentum sub-score of 89.7 driving the overall Alpha Score of 61.6. Revenue grew 8.1% year over year, but EPS fell 7.8% to $8.62, a divergence that leaves the stock trading at 29.9 times trailing earnings. The net margin of 21.5% remains a bright spot, though the value score of 39.3 reflects the premium multiple. Investors will watch next quarter's revenue mix — particularly whether the medtech and pharmaceutical segments can sustain growth without further margin compression. The sentiment score of 50 suggests neutral positioning, leaving room for either a breakout or a pullback from current levels.

Johnson & Johnson shares sit near the top of their 52-week range at $267.24, with the stock up roughly 60% from the $164.74 low. The big story is earnings. EPS jumped 320% year-over-year to $8.44, though that figure reflects a one-time gain tied to the Kenvue spin-off. Revenue growth came in at 8.1%, steady for a healthcare giant. Net margin sits at 21.5%, a solid number that supports the quality score of 75.2. The Alpha Score of 63.5 is respectable, but the breakdown shows a split. Momentum scores 83, which tracks with the price action near highs. Quality at 75.2 reinforces the margin story. The drag is value at 39.2. A P/E of 30.72 is rich for a company growing revenue in the single digits. Sentiment sits at 50, neutral. What to watch next quarter: whether the revenue growth rate accelerates or the P/E compresses. The stock's current valuation leaves little room for a miss.